Weimou Biotechnology (Zhejiang) Co., Ltd. has successfully concluded a D2+ funding round, raising over RMB 100 million. This round was spearheaded by Ouhai Xiangtou and joined by new investors including Guangdong Science and Technology Finance Group and Renze Zhenhe, alongside increased participation from existing shareholders. The procured funds will be strategically allocated to accelerate the mid-to-late clinical trials of the company's core product pipelines, enhance its preclinical research and development capabilities, and bolster its technological innovation platforms. Weimou Biotech, a specialist in the research and development of ophthalmic innovative drugs, boasts multiple core pipelines currently at crucial clinical stages. Notably, VVN461LD has garnered positive feedback from the FDA, VVN461HD has been listed on the National Medical Products Administration's (NMPA) "Breakthrough Therapy Drug List," and VVN001 and VVN1901 have advanced to Phase III and Phase II clinical trials, respectively.